Abbott Laboratories Return on Investment 2012-2025 | ABT
Current and historical return on investment (ROI) values for Abbott Laboratories (ABT) over the last 10 years.
| Abbott Laboratories ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2025-09-30 | $7.71B | $62.86B | 12.39% |
| 2025-06-30 | $7.52B | $63.76B | 12.58% |
| 2025-03-31 | $7.13B | $61.80B | 12.52% |
| 2024-12-31 | $6.83B | $60.53B | 12.54% |
| 2024-09-30 | $6.69B | $52.85B | 12.77% |
| 2024-06-30 | $6.48B | $52.70B | 12.41% |
| 2024-03-31 | $6.36B | $51.62B | 12.21% |
| 2023-12-31 | $6.48B | $52.43B | 12.43% |
| 2023-09-30 | $6.00B | $52.17B | 11.58% |
| 2023-06-30 | $6.13B | $51.97B | 11.87% |
| 2023-03-31 | $6.96B | $51.85B | 13.39% |
| 2022-12-31 | $8.36B | $51.43B | 16.02% |
| 2022-09-30 | $9.44B | $51.18B | 17.91% |
| 2022-06-30 | $10.21B | $53.47B | 19.31% |
| 2022-03-31 | $9.23B | $52.72B | 17.60% |
| 2021-12-31 | $8.43B | $53.32B | 16.18% |
| 2021-09-30 | $8.48B | $52.08B | 16.43% |
| 2021-06-30 | $7.43B | $51.58B | 14.54% |
| 2021-03-31 | $6.71B | $51.28B | 13.30% |
| 2020-12-31 | $5.36B | $51.53B | 10.84% |
| 2020-09-30 | $4.31B | $49.94B | 8.89% |
| 2020-06-30 | $4.02B | $48.98B | 8.29% |
| 2020-03-31 | $4.55B | $47.23B | 9.30% |
| 2019-12-31 | $4.53B | $47.96B | 9.13% |
| 2019-09-30 | $4.31B | $49.66B | 8.59% |
| 2019-06-30 | $4.11B | $50.88B | 8.16% |
| 2019-03-31 | $3.78B | $49.97B | 7.53% |
| 2018-12-31 | $3.65B | $50.08B | 7.17% |
| 2018-09-30 | $3.14B | $50.18B | 5.92% |
| 2018-06-30 | $2.91B | $50.60B | 5.36% |
| 2018-03-31 | $2.41B | $52.76B | 4.35% |
| 2017-12-31 | $1.56B | $58.31B | 2.78% |
| 2017-09-30 | $1.70B | $55.53B | 3.28% |
| 2017-06-30 | $1.83B | $55.60B | 4.09% |
| 2017-03-31 | $2.26B | $55.31B | 6.01% |
| 2016-12-31 | $3.03B | $41.40B | 9.93% |
| 2016-09-30 | $3.05B | $26.87B | 11.34% |
| 2016-06-30 | $2.87B | $26.81B | 10.62% |
| 2016-03-31 | $2.78B | $26.82B | 10.10% |
| 2015-12-31 | $2.87B | $27.20B | 10.31% |
| 2015-09-30 | $2.88B | $27.17B | 10.56% |
| 2015-06-30 | $2.90B | $28.99B | 10.66% |
| 2015-03-31 | $2.84B | $27.92B | 10.65% |
| 2014-12-31 | $2.60B | $25.03B | 9.83% |
| 2014-09-30 | $2.19B | $26.71B | 8.00% |
| 2014-06-30 | $1.93B | $27.11B | 7.04% |
| 2014-03-31 | $1.88B | $26.88B | 6.94% |
| 2013-12-31 | $2.13B | $28.66B | 7.91% |
| 2013-09-30 | $1.69B | $27.19B | 5.45% |
| 2013-06-30 | $1.53B | $25.84B | 4.50% |
| 2013-03-31 | $1.47B | $26.15B | 3.99% |
| 2012-12-31 | $1.36B | $44.90B | 3.44% |
| 2012-09-30 | $3.47B | $39.16B | 9.26% |
| 2012-06-30 | $3.75B | $36.58B | 10.11% |
| 2012-03-31 | $4.96B | $37.41B | 13.15% |
| 2011-12-31 | $5.75B | $36.57B | 15.26% |
| 2011-09-30 | $5.50B | $37.79B | 14.72% |
| 2011-06-30 | $6.09B | $39.10B | 16.67% |
| 2011-03-31 | $5.92B | $37.25B | 16.96% |
| 2010-12-31 | $6.09B | $35.29B | 18.15% |
| 2010-09-30 | $6.12B | $34.39B | 18.36% |
| 2010-06-30 | $6.58B | $32.61B | 19.95% |
| 2010-03-31 | $6.65B | $31.89B | 20.35% |
| 2009-12-31 | $6.24B | $34.45B | 19.43% |
| 2009-09-30 | $6.12B | $32.95B | 20.36% |
| 2009-06-30 | $5.87B | $31.29B | 20.28% |
| 2009-03-31 | $5.61B | $29.66B | 19.85% |
| 2008-12-31 | $5.70B | $26.23B | 20.63% |
| 2008-09-30 | $5.47B | $28.61B | 19.63% |
| 2008-06-30 | $5.00B | $28.53B | 19.06% |
| 2008-03-31 | $4.78B | $27.02B | 19.43% |
| 2007-12-31 | $4.58B | $27.31B | 19.87% |
| 2007-09-30 | $2.83B | $22.09B | 13.17% |
| 2007-06-30 | $2.59B | $21.94B | 11.91% |
| 2007-03-31 | $1.95B | $20.86B | 8.81% |
| 2006-12-31 | $2.04B | $21.06B | 9.48% |
| 2006-09-30 | $3.58B | $23.14B | 17.01% |
| 2006-06-30 | $3.72B | $23.36B | 19.01% |
| 2006-03-31 | $4.27B | $18.59B | 23.08% |
| 2005-12-31 | $4.36B | $18.99B | 23.50% |
| 2005-09-30 | $4.19B | $17.31B | 22.53% |
| 2005-06-30 | $4.38B | $19.10B | 23.45% |
| 2005-03-31 | $4.08B | $18.88B | 22.32% |
| 2004-12-31 | $3.90B | $19.11B | 21.42% |
| 2004-09-30 | $3.71B | $17.68B | 21.16% |
| 2004-06-30 | $3.51B | $17.51B | 20.57% |
| 2004-03-31 | $2.94B | $18.47B | 17.58% |
| 2003-12-31 | $2.97B | $16.53B | 18.54% |
| 2003-09-30 | $2.54B | $15.77B | 16.24% |
| 2003-06-30 | $2.63B | $16.21B | 17.04% |
| 2003-03-31 | $3.09B | $15.64B | 20.62% |
| 2002-12-31 | $3.15B | $14.94B | 21.74% |
| 2002-09-30 | $3.36B | $15.00B | 23.78% |
| 2002-06-30 | $3.19B | $14.29B | 23.42% |
| 2002-03-31 | $3.10B | $13.77B | 23.41% |
| 2001-12-31 | $1.90B | $13.40B | 15.65% |
| 2001-09-30 | $2.10B | $13.01B | 18.82% |
| 2001-06-30 | $2.14B | $12.87B | 20.87% |
| 2001-03-31 | $2.39B | $9.18B | 25.30% |
| 2000-12-31 | $3.40B | $9.65B | 36.04% |
| 2000-09-30 | $3.27B | $9.39B | 35.50% |
| 2000-06-30 | $3.06B | $9.51B | 34.53% |
| 2000-03-31 | $3.05B | $9.20B | 36.16% |
| 1999-12-31 | $3.12B | $8.76B | 39.02% |
| 1999-09-30 | $3.17B | $8.01B | 41.88% |
| 1999-06-30 | $3.29B | $7.78B | 45.52% |
| 1999-03-31 | $3.24B | $7.40B | 46.98% |
| 1998-12-31 | $3.13B | $7.05B | 47.25% |
| 1998-09-30 | $3.07B | $6.72B | 48.35% |
| 1998-06-30 | $2.99B | $6.45B | 48.83% |
| 1998-03-31 | $2.92B | $6.28B | 48.89% |
| 1997-12-31 | $2.85B | $5.94B | 48.77% |
| 1997-09-30 | $2.79B | $5.78B | 48.04% |
| 1997-06-30 | $2.74B | $5.87B | 48.04% |
| 1997-03-31 | $2.68B | $5.79B | 48.69% |
| 1996-12-31 | $2.62B | $5.75B | 49.35% |
| 1996-09-30 | $2.56B | $5.40B | 50.40% |
| 1996-06-30 | $2.53B | $5.07B | 51.51% |
| 1996-03-31 | $2.47B | $5.00B | 51.38% |
| 1995-12-31 | $2.38B | $4.83B | 51.14% |
| 1995-09-30 | $2.32B | $4.71B | 51.09% |
| 1995-06-30 | $2.26B | $4.68B | 51.04% |
| 1995-03-31 | $2.21B | $4.42B | 51.36% |
| 1994-12-31 | $2.14B | $4.34B | 50.97% |
| 1994-09-30 | $2.10B | $4.27B | 50.95% |
| 1994-06-30 | $2.06B | $4.16B | 51.80% |
| 1994-03-31 | $1.94B | $4.06B | 50.30% |
| 1993-12-31 | $1.85B | $3.98B | 49.85% |
| 1993-09-30 | $1.78B | $3.70B | 49.58% |
| 1993-06-30 | $1.78B | $3.65B | 50.43% |
| 1993-03-31 | $1.77B | $3.55B | 51.04% |
| 1992-12-31 | $1.74B | $3.46B | 50.63% |
| 1992-09-30 | $1.73B | $3.44B | 50.87% |
| 1992-06-30 | $1.64B | $3.46B | 49.30% |
| 1992-03-31 | $1.60B | $3.40B | 49.35% |
| 1991-12-31 | $1.56B | $3.33B | 49.33% |
| 1991-09-30 | $1.50B | $3.14B | 48.88% |
| 1991-06-30 | $1.47B | $3.09B | 49.12% |
| 1991-03-31 | $1.45B | $3.07B | 49.35% |
| 1990-12-31 | $1.41B | $2.97B | 48.59% |
| 1990-09-30 | $1.37B | $2.84B | 47.60% |
| 1990-06-30 | $1.32B | $2.88B | 45.90% |
| 1990-03-31 | $1.27B | $2.90B | 44.20% |
| 1989-12-31 | $1.22B | $2.87B | 42.74% |
| 1989-09-30 | $1.17B | $2.87B | 41.20% |
| 1989-06-30 | $1.14B | $2.82B | 41.10% |
| 1989-03-31 | $1.12B | $2.87B | 41.14% |
| 1988-12-31 | $1.10B | $2.81B | 42.30% |
| 1988-09-30 | $1.09B | $2.62B | 43.57% |
| 1988-06-30 | $1.07B | $2.58B | 44.68% |
| 1988-03-31 | $1.04B | $2.41B | 45.14% |
| 1987-12-31 | $1.01B | $2.36B | 45.06% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $218.959B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EssilorLuxottica (ESLOY) | France | $150.458B | 0.00 |
| Boston Scientific (BSX) | United States | $144.746B | 33.10 |
| Stryker (SYK) | United States | $140.556B | 27.91 |
| Medtronic (MDT) | Ireland | $125.035B | 17.32 |
| Medline (MDLN) | United States | $53.232B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.704B | 0.00 |
| Agilent Technologies (A) | United States | $42.105B | 26.62 |
| GE HealthCare Technologies (GEHC) | United States | $39.758B | 19.01 |
| ResMed (RMD) | United States | $36.846B | 25.50 |
| Koninklijke Philips (PHG) | Netherlands | $28.483B | 18.60 |
| Terumo (TRUMY) | Japan | $21.735B | 24.47 |
| Insulet (PODD) | United States | $20.333B | 63.11 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.401B | 11.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.263B | 0.00 |
| Baxter (BAX) | United States | $10.831B | 8.74 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.735B | 31.41 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.480B | 13.65 |
| BillionToOne (BLLN) | United States | $3.933B | 0.00 |
| Envista Holdings (NVST) | United States | $3.885B | 22.29 |
| Haemonetics (HAE) | United States | $3.840B | 17.09 |
| ICU Medical (ICUI) | United States | $3.777B | 23.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.086B | 14.07 |
| QuidelOrtho (QDEL) | United States | $2.286B | 14.69 |
| Neogen (NEOG) | United States | $2.093B | 45.81 |
| Perrigo (PRGO) | Ireland | $2.075B | 5.20 |
| AtriCure (ATRC) | United States | $2.061B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.928B | 38.81 |
| Curaleaf Holdings (CURLF) | Canada | $1.716B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.680B | 73.64 |
| Phibro Animal Health (PAHC) | United States | $1.599B | 15.97 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.577B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.425B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.421B | 20.57 |
| BioLife Solutions (BLFS) | United States | $1.197B | 355.14 |
| Capricor Therapeutics (CAPR) | United States | $1.090B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.031B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.005B | 0.00 |
| InMode (INMD) | Israel | $0.913B | 10.31 |
| Omeros (OMER) | United States | $0.886B | 0.00 |
| CeriBell (CBLL) | United States | $0.865B | 0.00 |
| Valneva SE (VALN) | France | $0.850B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.563B | 15.26 |
| Verano Holdings (VRNO) | United States | $0.461B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.453B | 0.00 |
| Brainsway (BWAY) | Israel | $0.453B | 77.03 |
| Cresco Labs (CRLBF) | United States | $0.443B | 0.00 |
| SNDL (SNDL) | Canada | $0.436B | 0.00 |
| Cerus (CERS) | United States | $0.396B | 0.00 |
| Quanterix (QTRX) | United States | $0.376B | 0.00 |
| Evolus (EOLS) | United States | $0.366B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.290B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 21.94 |
| Sanuwave Health (SNWV) | United States | $0.266B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.242B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.00 |
| High Tide (HITI) | Canada | $0.234B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.217B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Vireo Growth (VREOF) | United States | $0.208B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.192B | 16.92 |
| Accendra Health (ACH) | United States | $0.190B | 1.91 |
| OraSure Technologies (OSUR) | United States | $0.189B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.154B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.137B | 0.00 |
| Apyx Medical (APYX) | United States | $0.133B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.118B | 0.00 |
| Biote (BTMD) | United States | $0.118B | 5.16 |
| MacroGenics (MGNX) | United States | $0.116B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.71 |
| ImmuCell (ICCC) | United States | $0.059B | 24.98 |
| Sharps Technology (STSS) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.051B | 37.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Jin Medical (ZJYL) | China | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.53 |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Bonk (BNKK) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Flora Growth (FLGC) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |